MargaretVRagniMD

Hematology • Pittsburgh, PA

Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Ragni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ragni's full profile

Already have an account?

Office
5115 Centre Ave
# Upmc
Pittsburgh, PA 15232
Phone+1 412-692-4724

Education & Training

University of Pittsburgh Graduate School of Public HealthMPH, Epidemiology, 1991 - 1993
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1978 - 1982
UPMC Medical EducationResidency, Internal Medicine, 1975 - 1978
University of Pittsburgh School of MedicineClass of 1975

Certifications & Licensure

PA State Medical License 1976 - 2024

Clinical Trials

Phase II Study of IL-11 (Neumega) in Von Willebrand Disease Start of enrollment: 2004 Jul 01
Completed
Phase 2
Rituximab to Treat Severe Hemophilia A Start of enrollment: 2006 Jun 01
Completed
Phase 2
LTFU for Gene Transfer Subjects With Hemophilia B Start of enrollment: 2007 Aug 01
Completed
IL-11 in Adults With Von Willebrand Disease Undergoing Surgery Start of enrollment: 2008 Feb 01
Terminated
Phase 2
IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia Start of enrollment: 2008 Jan 01
Completed
Phase 2
Efficacy and Safety of IL-11 in DDAVP Unresponsive Start of enrollment: 2010 Jan 01
Completed
Phase 2
Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A Start of enrollment: 2012 Jul 01
Terminated
Phase 3
Hemophilia B Gene Therapy With AAV8 Vector Start of enrollment: 2012 Oct 01
Terminated
Phase 1
Hemophilia Inhibitor Previously Untreated Patient Study Start of enrollment: 2011 Jul 01
Completed
Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome Start of enrollment: 2014 May 01
Terminated
Phase 2
Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform Start of enrollment: 2020 Aug 01
Withdrawn
Phase 3
Minimize Menorrhagia in Women With Von Willebrand Disease Start of enrollment: 2019 Feb 07
Terminated
Phase 3
ATHN 11: Liver Transplantation Outcomes Study Start of enrollment: 2020 Jun 18
Completed
Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial Start of enrollment: 2021 Jun 04
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

72 citations
Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.
Carla S. Coffin, Peter G. Stock, Lorna Dove, Carl L. Berg, Nicholas N. Nissen
American Journal of Transplantation. 2010-05-01
167 citations
Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.
Norah A. Terrault, Michelle E. Roland, Thomas D. Schiano, Lorna Dove, Michael T. Wong
Liver Transplantation. 2012-06-01
546 citations
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
Catherine S. Manno, Amy J. Chew, Sylvia Hutchison, Peter J. Larson, Roland W. Herzog
Blood. 2003-04-15

Journal Articles

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A
Doris V Quon, Margaret V Ragni, The New England Journal of Medicine

Abstracts/Posters

Mechanism of Pulmonary Thrombosis in Hemolytic Disorders
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Emicizumab Prophylaxis in Patients with Hemophilia _ with and without Inhibitors
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Fitusiran, an RNAi Therapeutic Targeting Antithrombin to Restore Hemostatic Balance in Patients with Hemophilia a or B with or without Inhibitors: Management of Acute ...
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance
Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Hemostasis and Thrombosis
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Scientific Communication: Explaining Your Science to a Lay Audience
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Authored Content

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX VariantDecember 2017

Press Mentions

Addressing Iron Deficiency Anemia and Related Disparities in PregnancyOctober 25th, 2024
Gene Therapy for Hemophilia B and an Update on Gene Therapy for Hemophilia A:November 2nd, 2022
Clinical Challenges: Getting to a Cure for Hemophilia in ChildhoodDecember 22nd, 2021
Join now to see all

Grant Support

Training Students In Biomedical Research In HematologyNational Heart, Lung, And Blood Institute2005–2012
Hemophilia Adult Prophylaxis StudyNational Heart, Lung, And Blood Institute2011
Ph2 Comp Hemostatic Of Escal Doses Interleukin-11 W/Type 1 Von Willebrand DISNational Center For Research Resources2005
Impact Of HIV On Hepatitis C In Hemophilia (3HS)National Center For Research Resources2004–2005
Ph1 Sfy Sty PTS W/Severe Hemophilia B Using AavvNational Center For Research Resources2004
Impact Of HIV On Hepatitis C Infection In HemophiliaNational Heart, Lung, And Blood Institute2001–2004
Factor VIII Vector For Severe Hemophilia ANational Center For Research Resources2000–2002
Epidemiology And Immunology Of Hemophilia A InhibitorsNational Heart, Lung, And Blood Institute1998–2001
Safety/Efficacy Of Kogenate 2 Antihemophilic Factor Recombinant Free Of AlbuminNational Center For Research Resources1998–1999
Safety And Efficacy Of Human Recombinant Factor (RHFIX) In Hemophilia B PatientsNational Center For Research Resources1998–1999
Safety &Efficacy Of Kogenate-2 Antihemophilic Factor RecombinantNational Center For Research Resources1997
Pharmacokinetic, Safety And Efficacy Study Of Human Recombinant Factor (RHFIX)National Center For Research Resources1997
Three-Segment, Phase I/II Study Of RH Factor IX In Patients With Hemophilia BNational Center For Research Resources1996
Study Of Hiv-Associated Malignancy In HemophiliacsNational Cancer Institute1989–1993
Hiv-Associated Malignancy In HemophiliacsNational Cancer Institute1992